Germany · Delayed Price · Currency is EUR Clover Health Investments Statistics
Total Valuation
FRA:7QD has a market cap or net worth of EUR 1.11 billion. The enterprise value is 947.63 million.
| Market Cap | 1.11B |
| Enterprise Value | 947.63M |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 424.30M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.78% |
| Shares Change (QoQ) | +0.73% |
| Owned by Insiders (%) | 21.35% |
| Owned by Institutions (%) | 26.22% |
| Float | 404.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 157.94 |
| PS Ratio | 0.74 |
| PB Ratio | 3.82 |
| P/TBV Ratio | 3.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.06 |
| EV / Sales | 0.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -12.87 |
Financial Position
The company has a current ratio of 1.71
| Current Ratio | 1.71 |
| Quick Ratio | 1.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.90% and return on invested capital (ROIC) is -10.49%.
| Return on Equity (ROE) | -16.90% |
| Return on Assets (ROA) | -5.94% |
| Return on Invested Capital (ROIC) | -10.49% |
| Return on Capital Employed (ROCE) | -15.74% |
| Revenue Per Employee | 2.65M |
| Profits Per Employee | -87,205 |
| Employee Count | 570 |
| Asset Turnover | 2.93 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -34.33% |
| 50-Day Moving Average | 2.43 |
| 200-Day Moving Average | 2.70 |
| Relative Strength Index (RSI) | 43.69 |
| Average Volume (20 Days) | 324 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.86 |
Income Statement
In the last 12 months, FRA:7QD had revenue of EUR 1.51 billion and -49.71 million in losses. Loss per share was -0.10.
| Revenue | 1.51B |
| Gross Profit | 320.13M |
| Operating Income | -49.14M |
| Pretax Income | -49.19M |
| Net Income | -49.71M |
| EBITDA | -47.77M |
| EBIT | -49.14M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 172.88 million in cash and n/a in debt, giving a net cash position of 161.98 million.
| Cash & Cash Equivalents | 172.88M |
| Total Debt | n/a |
| Net Cash | 161.98M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 290.58M |
| Book Value Per Share | 0.57 |
| Working Capital | 117.17M |
Cash Flow
In the last 12 months, operating cash flow was -72.12 million and capital expenditures -1.50 million, giving a free cash flow of -73.62 million.
| Operating Cash Flow | -72.12M |
| Capital Expenditures | -1.50M |
| Free Cash Flow | -73.62M |
| FCF Per Share | n/a |
Margins
Gross margin is 21.18%, with operating and profit margins of -3.25% and -3.29%.
| Gross Margin | 21.18% |
| Operating Margin | -3.25% |
| Pretax Margin | -3.25% |
| Profit Margin | -3.29% |
| EBITDA Margin | -3.16% |
| EBIT Margin | -3.25% |
| FCF Margin | n/a |
Dividends & Yields
FRA:7QD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.78% |
| Shareholder Yield | -3.78% |
| Earnings Yield | -4.47% |
| FCF Yield | -6.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |